I'm not chasing hype—I'm after real value. HIMS & HERS Health has skyrocketed 155% this year, but what matters to me is whether it's trading below its intrinsic value. With sticky subscriptions, strong gross margins, and zero debt, it's a legit disruptor in the health tech space, even if shareholder

AI-generated source summary

The analysis covers Hims & Hers Health (HIMS), a health tech disruptor up 155% YTD. It focuses on real companies, cash flow, and opportunities, not hype. The stock chart is volatile, with significant ups and downs. The market reacts to every new story, but the analysis asks if it's selling at a fair price. The company has strong revenue with an 85% two-year retention rate on their subscription model. The ticker symbol is HIMS, and they are in telehealth, mental health, dermatology, and GLP-1 weight loss. They disrupt healthcare by reimagining the patient experience and have an economic moat factor (narrow). There are about 222 million shares outstanding (diluting shareholders), but there is zero debt. The main metric is the enterprise value. With the return on capital now positive this is a buying opportunity. Key metrics reviewed include market cap, revenue, net income, free cash flow, price to free cash flow, gross profit margin, 3Y compound revenue growth, 5-year revenue, and return on invested capital, the average investor has a hold recommendation. 10, 20, and 30 percent revenue growth for the next 10 years were assumed in the Everything Money Stock Analyzer, resulting in an intrinsic value that is 16.59% above the current stock price. There is potential to make more money using technical strategies and the smaller chart timeframes.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   05 Aug 2025, 09:54 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   29 Jul 2026, 03:08 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   29 Jul 2026, 03:08 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   29 Jul 2026, 03:08 UTC

   All evaluable predictions in this case reached terminal outcomes.